AstraZeneca to take over Fusion Therapeutics Inc
Fusion Pharmaceuticals Inc‘s acquisition for US$2bn upfront marks a major step forward in AstraZeneca delivering on its ambition to transform cancer...
SynaptixBio Ltd gets FDA ODD for leukodystrophy
Using antisense oligonucleotides (ASO) to silence the beta tubulin 4a gene, Oxford-based SynaptixBio Ltd received its first ODD in early 2023 for a...
New law to speed up clinical trials
The draft Medical Research Act (Medizinforschungsgesetz) presented by Health Minister Karl Lauterbach in Berlin before Easter is the centrepiece of...
EU parliament backs deregulation of New Genome Techniques
With the MEPs' approval of the amendments to the European Commission's draft legislation, the way is now clear for a regulation that distinguishes...
Innocent Meat bags €3m financing
The three-year-old startup announced it will use the new proceeds to optimise components of its automated plug-and-produce solution for mass...
Bayer's Ask Bio unit starts Phase II heart failure gene therapy
The Phase II trial called GenePHIT is the largest adaptive, double-blind, placebo-controlled, randomised, multicentre trial ever to evaluate the...
Forbion participates in US financing rounds
Forbion is throwing a few million into the ring in order to participate in oversubscribed financing rounds in the USA. Both Series B financings have...